Table 1.
Age group (years) | Positive no./examined no. (%) | Assemblage (n) | Sub-assemblage (n)/accession no. | MLGs (n) | ||
---|---|---|---|---|---|---|
SSU rRNA | bg | tpi | gdh | |||
Children (< 5) | 0/26 | |||||
Minors (5–17)a | 22/225 (9.78) | A (3) | AII (1)/OM001823 | AII (1)/OM001842 | AII (1)/OM001857 | MLG-AII (1) |
B (19) | B1 (1)/OM001858 | |||||
B1 (1)/OM001824 | B1 (1)/OM001843 | B2 (1)/OM001859 | MLG-B1 (1) | |||
Young adults (18–35) | 0/31 | |||||
Middle-aged adults (36–60)a | 1/83 (1.20) | A (1) | AII (1)/OM001823 | |||
Older adults (> 60) | 1/48 (2.08) | A (1) | ||||
Total | 24/413 (5.81) | A (5), B (19) | AII (2), B1 (1) | AII (1), B1 (1) | AII (1), B1 (1), B2 (1) |
One novel sequence obtained in the present study is highlighted in bold
aA significant difference in prevalence is observed only between the age groups of 5–17 and 36–60 years